- •Preface to the First Edition
- •Preface to the Second Edition
- •Contents
- •Diagnostic Challenges
- •Expert Centers
- •Patient Organizations
- •Clinical Trials
- •Research in Orphan Lung Diseases
- •Orphan Drugs
- •Orphanet
- •Empowerment of Patients
- •Conclusions
- •References
- •Introduction
- •Challenges to Overcome in Order to Undertake Quality Clinical Research
- •Lack of Reliable Data on Prevalence
- •Small Number of Patients
- •Identifying Causation/Disease Pathogenesis
- •Disease Complexity
- •Lack of Access to a Correct Diagnosis
- •Delay in Diagnosis
- •Challenges But Not Negativity
- •Some Success Stories
- •The Means to Overcome the Challenges of Clinical Research: Get Bigger Numbers of Well-Characterized Patients
- •The Importance of Patient Organizations
- •National and International Networks
- •End Points for Trials: Getting Them Right When Numbers Are Small and Change Is Modest
- •Orphan Drug Development
- •Importance of Referral Centers
- •Looking at the Future
- •The Arguments for Progress
- •Concluding Remarks
- •References
- •3: Chronic Bronchiolitis in Adults
- •Introduction
- •Cellular Bronchiolitis
- •Follicular Bronchiolitis
- •Respiratory Bronchiolitis
- •Airway-Centered Interstitial Fibrosis
- •Proliferative Bronchiolitis
- •Diagnosis
- •Chest Imaging Studies
- •Pulmonary Function Testing
- •Lung Biopsy
- •Mineral Dusts
- •Organic Dusts
- •Volatile Flavoring Agents
- •Infectious Causes of Bronchiolitis
- •Idiopathic Forms of Bronchiolitis
- •Connective Tissue Diseases
- •Organ Transplantation
- •Hematopoietic Stem Cell Transplantation
- •Drug-Induced Bronchiolitis
- •Treatment
- •Constrictive Bronchiolitis
- •Follicular Bronchiolitis
- •Airway-Centered Interstitial Fibrosis
- •Proliferative Bronchiolitis
- •References
- •Background and Epidemiology
- •Pathophysiology
- •Host Characteristics
- •Clinical Manifestations
- •Symptoms
- •Laboratory Evaluation
- •Skin Testing
- •Serum Precipitins
- •Eosinophil Count
- •Total Serum Immunoglobulin E Levels
- •Recombinant Antigens
- •Radiographic Imaging
- •Pulmonary Function Testing
- •Histology
- •Diagnostic Criteria
- •Historical Diagnostic Criteria
- •Rosenberg and Patterson Diagnostic Criteria
- •ISHAM Diagnostic Criteria
- •Cystic Fibrosis Foundation Diagnostic Criteria
- •General Diagnostic Recommendations
- •Allergic Aspergillus Sinusitis (AAS)
- •Natural History
- •Treatment
- •Corticosteroids
- •Antifungal Therapy
- •Monoclonal Antibodies
- •Monitoring for Treatment Response
- •Conclusions
- •References
- •5: Orphan Tracheopathies
- •Introduction
- •Anatomical Considerations
- •Clinical Presentation
- •Etiological Considerations
- •Idiopathic Subglottic Stenosis
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Introduction and Clinical Presentation
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheomalacia
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheobronchomegaly
- •Introduction
- •Clinical Features
- •Pathophysiology
- •Pulmonary Function Studies
- •Imaging Studies
- •Treatment
- •Tracheopathies Associated with Systemic Diseases
- •Relapsing Polychondritis
- •Introduction
- •Clinical Features
- •Laboratory Findings
- •Pulmonary Function and Imaging Studies
- •Treatment
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheobronchial Amyloidosis
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Sarcoidosis
- •Introduction
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Orphan Tracheopathies: Conclusions
- •References
- •6: Amyloidosis and the Lungs and Airways
- •Introduction
- •Diagnosis and Evaluation of Amyloidosis
- •Systemic AA Amyloidosis
- •Systemic AL Amyloidosis
- •Amyloidosis Localised to the Respiratory Tract
- •Laryngeal Amyloidosis
- •Tracheobronchial Amyloidosis
- •Parenchymal Pulmonary Amyloidosis
- •Pulmonary Amyloidosis Associated with Sjögren’s Disease
- •Conclusions
- •References
- •Introduction
- •Pathophysiology
- •Genetic Predisposition
- •Immune Dysregulation
- •Epidemiology
- •Incidence and Prevalence
- •Triggering Factors
- •Clinical Manifestations
- •General Symptoms
- •Pulmonary Manifestations
- •Ear, Nose, and Throat (ENT) Manifestations
- •Neurological Manifestations
- •Skin Manifestations
- •Cardiac Manifestations
- •Gastrointestinal Involvement
- •Renal Manifestations
- •Ophthalmological Manifestations
- •Complementary Investigations
- •Diagnosis
- •Diagnostic Criteria
- •Prognosis and Outcomes
- •Phenotypes According to the ANCA Status
- •Treatment
- •Therapeutic Strategies
- •Remission Induction
- •Maintenance Therapy
- •Other Treatments
- •Prevention of AEs
- •Conclusions
- •References
- •8: Granulomatosis with Polyangiitis
- •A Brief Historical Overview
- •Epidemiology
- •Pathogenesis
- •Clinical Manifestations
- •Constitutional Symptoms
- •Ear, Nose, and Throat (ENT) Manifestations
- •Pulmonary Manifestations
- •Kidney and Urological Manifestations
- •Kidney Manifestations
- •Urological Manifestations
- •Neurological Manifestations
- •Peripheral Nervous System (PNS) Manifestations
- •Central Nervous System (CNS) Manifestations
- •Spinal Cord and Cranial Nerve Involvement
- •Skin and Oral Mucosal Manifestations
- •Eye Manifestations
- •Cardiac Involvement
- •Gastrointestinal Manifestations
- •Gynecological and Obstetric Manifestations
- •Venous Thrombosis and Other Vascular Events
- •Other Manifestations
- •Pediatric GPA
- •Diagnosis
- •Diagnostic Approach
- •Laboratory Investigations
- •Biology
- •Immunology
- •Pathology
- •Treatment
- •Glucocorticoids
- •Cyclophosphamide
- •Rituximab
- •Other Current Induction Approaches
- •Other Treatments in GPA
- •Intravenous Immunoglobulins
- •Plasma Exchange
- •CTLA4-Ig (Abatacept)
- •Cotrimoxazole
- •Other Agents
- •Principles of Treatment for Relapsing and Refractory GPA
- •Outcomes and Prognostic Factors
- •Survival and Causes of Deaths
- •Relapse
- •Damage and Disease Burden on Quality of Life
- •Conclusions
- •References
- •9: Alveolar Hemorrhage
- •Introduction
- •Clinical Presentation
- •Diagnosis (Table 9.1, Fig. 9.3)
- •Pulmonary Capillaritis
- •Histology (Fig. 9.4)
- •Etiologies
- •ANCA-Associated Small Vessel Vasculitis: Granulomatosis with Polyangiitis (GPA)
- •ANCA-Associated Small Vessel Vasculitis: Microscopic Polyangiitis
- •Isolated Pulmonary Capillaritis
- •Systemic Lupus Erythematosus
- •Antiphospholipid Antibody Syndrome
- •Anti-Basement Membrane Antibody Disease (Goodpasture Syndrome)
- •Lung Allograft Rejection
- •Others
- •Bland Pulmonary Hemorrhage (Fig. 9.5)
- •Histology
- •Etiologies
- •Idiopathic Pulmonary Hemosiderosis
- •Drugs and Medications
- •Coagulopathy
- •Valvular Heart Disease and Left Ventricular Dysfunction
- •Other
- •Histology
- •Etiologies
- •Hematopoietic Stem Cell Transplantation (HSCT)
- •Cocaine Inhalation
- •Acute Exacerbation of Interstitial Lung Disease
- •Acute Interstitial Pneumonia
- •Acute Respiratory Distress Syndrome
- •Miscellaneous Causes
- •Etiologies
- •Pulmonary Capillary Hemangiomatosis
- •Treatment
- •Conclusions
- •References
- •Takayasu Arteritis
- •Epidemiology
- •Pathologic Features
- •Pathogenesis
- •Clinical Features
- •Laboratory Findings
- •Imaging Studies
- •Therapeutic Management
- •Prognosis
- •Behçet’s Disease
- •Epidemiology
- •Pathologic Features
- •Pathogenesis
- •Diagnostic Criteria
- •Clinical Features
- •Pulmonary Artery Aneurysm
- •Pulmonary Artery Thrombosis
- •Pulmonary Parenchymal Involvement
- •Laboratory Findings
- •Imaging Studies
- •Therapeutic Management
- •Treatment of PAA
- •Treatment of PAT
- •Prognosis
- •References
- •Introduction
- •Portopulmonary Hypertension (PoPH)
- •Epidemiology and Risk Factors
- •Molecular Pathogenesis
- •PoPH Treatment
- •Hepatopulmonary Syndrome (HPS)
- •Epidemiology and Risk Factors
- •Molecular Pathogenesis
- •HPS Treatment
- •Conclusion
- •References
- •12: Systemic Sclerosis and the Lung
- •Introduction
- •Risk factors for SSc-ILD
- •Genetic Associations
- •Clinical Presentation of SSc-ILD
- •Pulmonary Function Tests (PFTs)
- •Imaging
- •Management
- •References
- •13: Rheumatoid Arthritis and the Lungs
- •Introduction
- •Epidemiology
- •Risk Factors for ILD (Table 13.3)
- •Pathogenesis
- •Clinical Features and Diagnosis
- •Treatments
- •Prognosis
- •Epidemiology
- •Risk Factors
- •Clinical Features, Diagnosis, and Outcome
- •Subtypes or RA-AD
- •Obliterative Bronchiolitis
- •Bronchiectasis
- •COPD
- •Cricoarytenoid Involvement
- •Pleural Disease
- •Conclusion
- •References
- •Introduction
- •Systemic Lupus Erythematosus
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Pleural Disease
- •Shrinking Lung Syndrome
- •Thrombotic Manifestations
- •Interstitial Lung Disease
- •Other Pulmonary Manifestations
- •Prognosis
- •Sjögren’s Syndrome
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Airway Disorders
- •Lymphoproliferative Disease
- •Interstitial Lung Disease
- •Prognosis
- •Mixed Connective Tissue Disease
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Pulmonary Hypertension
- •Interstitial Lung Disease
- •Prognosis
- •Myositis
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations and Treatments
- •Interstitial Lung Disease
- •Respiratory Muscle Weakness
- •Other Pulmonary Manifestations
- •Prognosis
- •Other Therapeutic Options in CTD-ILD
- •Lung Transplantation
- •Conclusion
- •References
- •Introduction
- •Diagnostic Criteria
- •Controversies in the Diagnostic Criteria
- •Typical Clinical Features
- •Disease Progression and Prognosis
- •Summary
- •References
- •Introduction
- •Histiocytes and Dendritic Cells
- •Introduction
- •Cellular and Molecular Pathogenesis
- •Pathology
- •Clinical Presentation
- •Treatment and Prognosis
- •Erdheim-Chester Disease
- •Epidemiology
- •Cellular and Molecular Pathogenesis
- •Histopathology and Immunohistochemistry
- •Clinical Presentation
- •Investigation/Diagnosis
- •Chest Studies
- •Cardiovascular Imaging
- •CNS Imaging
- •Bone Radiography
- •Other Imaging Findings and Considerations
- •Disease Monitoring
- •Pathology
- •Management/Treatment
- •Prognosis
- •Rosai-Dorfman Destombes Disease
- •Epidemiology
- •Etiology/Pathophysiology
- •Histopathology and Immunohistochemistry
- •Clinical Presentation
- •Investigation/Diagnosis
- •Management/Treatment
- •Prognosis
- •Conclusions
- •Diagnostic Criteria for Primary Histiocytic Disorders of the Lung
- •References
- •17: Eosinophilic Pneumonia
- •Introduction
- •Eosinophil Biology
- •Physiologic and Immunologic Role of Eosinophils
- •Release of Mediators
- •Targeting the Eosinophil Cell Lineage
- •Historical Perspective
- •Clinical Presentation
- •Pathology
- •Diagnosis
- •Eosinophilic Lung Disease of Undetermined Cause
- •Idiopathic Chronic Eosinophilic Pneumonia
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Bronchoalveolar Lavage
- •Lung Function Tests
- •Treatment
- •Outcome and Perspectives
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Bronchoalveolar Lavage
- •Lung Function Tests
- •Lung Biopsy
- •Treatment and Prognosis
- •Eosinophilic Granulomatosis with Polyangiitis
- •History and Nomenclature
- •Pathology
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Pathogenesis
- •Diagnosis
- •Treatment and Prognosis
- •Long-Term Outcome
- •Hypereosinophilic Syndrome
- •Pathogenesis
- •Clinical and Imaging Features
- •Laboratory Studies
- •Treatment and Prognosis
- •Eosinophilic Pneumonias of Parasitic Origin
- •Tropical Eosinophilia [191]
- •Ascaris Pneumonia
- •Eosinophilic Pneumonia in Larva Migrans Syndrome
- •Strongyloides Stercoralis Infection
- •Eosinophilic Pneumonias in Other Infections
- •Allergic Bronchopulmonary Aspergillosis
- •Pathogenesis
- •Diagnostic Criteria
- •Biology
- •Imaging
- •Treatment
- •Bronchocentric Granulomatosis
- •Miscellaneous Lung Diseases with Associated Eosinophilia
- •References
- •Introduction
- •Pulmonary Langerhans’ Cell Histiocytosis
- •Epidemiology
- •Pathogenesis
- •Diagnosis
- •Clinical Features
- •Extrathoracic Lesions
- •Pulmonary Function Tests
- •Chest Radiography
- •High-Resolution Computed Tomography (HRCT)
- •Bronchoscopy and Bronchoalveolar Lavage (BAL)
- •Lung Biopsy
- •Pathology
- •Treatment
- •Course and Prognosis
- •Case Report I
- •Introduction
- •Epidemiology
- •Clinical Features
- •Histopathological Findings
- •Radiologic Findings
- •Prognosis and Therapy
- •Desquamative Interstitial Pneumonia
- •Epidemiologic and Clinical Features
- •Histopathological Findings
- •Radiological Findings
- •Prognosis and Therapy
- •Conclusion
- •References
- •19: Lymphangioleiomyomatosis
- •Introduction
- •Pathogenesis
- •Presentation
- •Prognosis
- •Management
- •General Measures
- •Parenchymal Lung Disease
- •Pleural Disease
- •Renal Angiomyolipoma
- •Abdominopelvic Lymphatic Disease
- •Pregnancy
- •Tuberous Sclerosis
- •Drug Treatment
- •Bronchodilators
- •mTOR Inhibitors
- •Anti-Oestrogen Therapy
- •Experimental Therapies
- •Interventions for Advanced Disease
- •Oxygen Therapy
- •Pulmonary Hypertension
- •References
- •20: Diffuse Cystic Lung Disease
- •Introduction
- •Lymphangioleiomyomatosis
- •Pathogenesis
- •Pathologic and Radiographic Characteristics
- •Diagnostic Approach
- •Pulmonary Langerhans Cell Histiocytosis (PLCH)
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Birt-Hogg-Dubé Syndrome (BHD)
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Lymphoproliferative Disorders
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Amyloidosis
- •Light Chain Deposition Disease (LCDD)
- •Conclusion
- •References
- •Introduction
- •Lymphatic Development
- •Clinical Presentation of Lymphatic Disorders
- •Approaches to Diagnosis and Management of Congenital Lymphatic Anomalies
- •Generalized Lymphatic Anomaly
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Course/Prognosis
- •Management
- •Kaposiform Lymphangiomatosis
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Gorham Stout Disease
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Channel-Type LM/Central Conducting LM
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Yellow Nail Syndrome
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Summary
- •References
- •Introduction
- •Historical Note
- •Epidemiology
- •Pathogenesis
- •Surfactant Homeostasis in PAP
- •GM-CSF Signaling Disruption
- •Myeloid Cell Dysfunction
- •GM-CSF Autoantibodies
- •Lymphocytosis
- •Clinical Manifestations
- •Clinical Presentation
- •Secondary Infections
- •Pulmonary Fibrosis
- •Diagnosis
- •Pulmonary Function Testing
- •Radiographic Assessment
- •Bronchoscopy and Bronchoalveolar Lavage
- •Laboratory Studies and Biomarkers
- •GM-CSF Autoantibodies
- •Genetic Testing
- •Lung Pathology
- •Diagnostic Approach to the Patient with PAP
- •Natural History and Prognosis
- •Treatment
- •Whole-Lung Lavage
- •Subcutaneous GM-CSF
- •Inhaled GM-CSF
- •Other Approaches
- •Conclusions and Future Directions
- •References
- •Introduction
- •Epidemiology
- •Gastric Contents
- •Pathobiology of GER/Microaspirate in the Lungs of Patients with IPF
- •GER and the Microbiome
- •Diagnosis
- •Clinical History/Physical Exam
- •Investigations
- •Esophageal Physiology
- •Upper Esophageal Sphincter
- •Esophagus and Peristalsis
- •Lower Esophageal Sphincter and Diaphragm
- •Esophageal pH and Impedance Testing
- •High Resolution Esophageal Manometry
- •Esophagram/Barium Swallow
- •Bronchoalveolar Lavage/Sputum: Biomarkers
- •Treatment
- •Anti-Acid Therapy (PPI/H2 Blocker)
- •GER and Acute Exacerbations of IPF
- •Suggested Approach
- •Summary and Future Directions
- •References
- •Introduction
- •Familial Interstitial Pneumonia
- •Telomere Related Genes
- •Genetic
- •Telomere Length
- •Pulmonary Involvement
- •Interstitial Lung Disease
- •Other Lung Disease
- •Hepatopulmonary Syndrome
- •Emphysema
- •Extrapulmonary Manifestations
- •Mucocutaneous Involvement
- •Hematological Involvement
- •Liver Involvement
- •Other Manifestations
- •Treatment
- •Telomerase Complex Agonists
- •Lung Transplantation
- •Surfactant Pathway
- •Surfactant Protein Genes
- •Pulmonary Involvement
- •Treatment
- •Heritable Forms of Pulmonary Fibrosis with Autoimmune Features
- •TMEM173
- •COPA
- •Pulmonary Alveolar Proteinosis
- •GMCSF Receptor Mutations
- •GATA2
- •MARS
- •Lysinuric Protein Intolerance
- •Lysosomal Diseases
- •Hermansky-Pudlak Syndrome
- •Lysosomal Storage Disorders
- •FAM111B, NDUFAF6, PEPD
- •Conclusion
- •References
- •Introduction
- •Pathophysiology
- •Clinical Presentation
- •Epidemiology
- •Genetic Causes of Bronchiectasis
- •Disorders of Mucociliary Clearance
- •Cystic Fibrosis
- •Primary Ciliary Dyskinesia
- •Other Ciliopathies
- •X-Linked Agammaglobulinemia
- •Chronic Granulomatous Disease and Other Disorders of Neutrophil Function
- •Other Genetic Disorders Predisposing to Bronchiectasis
- •Idiopathic Bronchiectasis
- •Diagnosis of Bronchiectasis
- •Management of Patients with Bronchiectasis
- •Airway Clearance Therapy (ACT)
- •Management of Infections
- •Immune Therapy
- •Surgery
- •Novel Therapies for Managing Cystic Fibrosis
- •Summary
- •References
- •Pulmonary Arteriovenous Malformations
- •Background Pulmonary AVMs
- •Anatomy Pulmonary AVMs
- •Clinical Presentation of Pulmonary AVMs
- •Screening Pulmonary AVMs
- •Treatment Pulmonary AVMs
- •Children with Hereditary Hemorrhagic Telangiectasia
- •Pulmonary Hypertension
- •Pulmonary Hypertension Secondary to Liver Vascular Malformations
- •Pulmonary Arterial Hypertension
- •Background HHT
- •Pathogenesis
- •References
- •27: Pulmonary Alveolar Microlithiasis
- •Introduction
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Diagnosis
- •Management
- •Summary
- •References
- •Introduction
- •Hermansky-Pudlak Syndrome
- •Telomerase-Associated Pulmonary Fibrosis
- •Lysosomal Storage Diseases
- •Lysinuric Protein Intolerance
- •Familial Hypocalciuric Hypercalcemia
- •Surfactant Dysfunction Disorders
- •Concluding Remarks
- •References
- •Introduction
- •Background
- •Image Acquisition
- •Key Features of Fibrosis
- •Ancillary Features of Fibrosis
- •Other Imaging Findings in FLD
- •Probable UIP-IPF
- •Indeterminate
- •Alternative Diagnosis
- •UIP in Other Fibrosing Lung Diseases
- •Pleuroparenchymal Fibroelastosis (PPFE)
- •Combined Pulmonary Fibrosis and Emphysema
- •Chronic Hypersensitivity Pneumonitis
- •Other Fibrosing Lung Diseases
- •Fibrosing Sarcoidosis
- •CTD-ILD and Drug-Induced FLD
- •Complications
- •Prognosis
- •Computer Analysis of CT Imaging
- •The Progressive Fibrotic Phenotype
- •Other Imaging Techniques
- •Conclusion
- •References
- •Introduction
- •Bronchoalveolar Lavage (BAL)
- •Technique
- •Interpretation
- •Transbronchial Biopsy (TBB)
- •Transbronchial Lung Cryobiopsy (TLCB)
- •References
- •Introduction
- •Overview of ILD Diagnosis
- •Clinical Assessment
- •Radiological Assessment
- •Laboratory Assessment
- •Integration of Individual Features
- •Multidisciplinary Discussion
- •Diagnostic Ontology
- •Conclusions
- •References
- •Introduction
- •Idiopathic Pulmonary Fibrosis
- •Chronic Hypersensitivity Pneumonitis
- •Connective Tissue Disease
- •Drug-Induced Lung Diseases
- •Radiation Pneumonitis
- •Asbestosis
- •Hermansky-Pudlak Syndrome
- •Risk Factors for Progression
- •Diagnosis
- •Pharmacological Management
- •Conclusions
- •References
- •Historical Perspective
- •Epidemiology and Etiologies
- •Tobacco Smoking and Male Sex
- •Genetic Predisposition
- •Systemic Diseases
- •Other Etiological Contexts
- •Clinical Manifestations
- •Pulmonary Function and Physiology
- •Imaging
- •Computed Tomography Characteristics and Patterns
- •Thick-Walled Large Cysts
- •Imaging Phenotypes
- •Pitfalls
- •Pathology
- •Diagnosis
- •CPFE Is a Syndrome
- •Biology
- •Complications and Outcome
- •Mortality
- •Pulmonary Hypertension
- •Lung Cancer
- •Acute Exacerbation of Pulmonary Fibrosis
- •Other Comorbidities and Complications
- •Management
- •General Measures and Treatment of Emphysema
- •Treatment of Pulmonary Fibrosis
- •Management of Pulmonary Hypertension
- •References
- •Acute Interstitial Pneumonia (AIP)
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Desquamative Interstitial Pneumonia (DIP)
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •References
- •Organizing Pneumonias
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Imaging
- •Multifocal Form
- •Isolated Nodular Form
- •Other Imaging Patterns
- •Histopathological Diagnosis of OP Pattern
- •Etiological Diagnosis of OP
- •Treatment
- •Clinical Course and Outcome
- •Severe Forms of OP with Respiratory Failure
- •Acute Fibrinous and Organizing Pneumonia
- •Granulomatous Organizing Pneumonia
- •Acute Interstitial Pneumonia
- •Epidemiology
- •Clinical Picture
- •Imaging
- •Histopathology
- •Diagnosis
- •Treatment
- •Outcome
- •References
- •36: Pleuroparenchymal Fibroelastosis
- •Introduction
- •Epidemiology
- •Clinical Manifestations
- •Laboratory Findings
- •Respiratory Function
- •Radiologic Features
- •Pathologic Features
- •Diagnosis
- •Treatment
- •Prognosis
- •Conclusions
- •References
- •Introduction
- •Acute Berylliosis
- •Chronic Beryllium Disease
- •Exposure
- •Epidemiology
- •Immunopathogenesis and Pathology
- •Genetics
- •Clinical Description and Natural History
- •Treatment and Monitoring
- •Indium–Tin Oxide-Lung Disease
- •Hard Metal Lung
- •Flock Worker’s Disease
- •Asbestosis
- •Nanoparticle Induced ILD
- •Flavoring-Induced Lung Disease
- •Silica-Induced Interstitial Lung Disease
- •Chronic Silicosis
- •Acute and Accelerated Silicosis
- •Chronic Obstructive Disease in CMDLD
- •Simple CMDLD
- •Complicated CMDLD
- •Conclusion
- •References
- •38: Unclassifiable Interstitial Lung Disease
- •Introduction
- •Diagnostic Scenarios
- •Epidemiology
- •Clinical Presentation
- •Diagnosis
- •Clinical Features
- •Radiology
- •Laboratory Investigations
- •Pathology
- •Conclusion
- •References
- •39: Lymphoproliferative Lung Disorders
- •Introduction
- •Nodular Lymphoid Hyperplasia
- •Lymphocytic Interstitial Pneumonia (LIP)
- •Follicular Bronchitis/Bronchiolitis
- •Castleman Disease
- •Primary Pulmonary Lymphomas
- •Primary Pulmonary MALT B Cell Lymphoma
- •Pulmonary Plasmacytoma
- •Follicular Lymphoma
- •Lymphomatoid Granulomatosis
- •Primary Pulmonary Hodgkin Lymphoma (PPHL)
- •Treatment
- •References
- •Introduction
- •Late-Onset Pulmonary Complications
- •Bronchiolitis Obliterans (BO)
- •Pathophysiology
- •Diagnosis
- •Management of BOS
- •Post-HSCT Organizing Pneumonia
- •Other Late-Onset NonInfectious Pulmonary Complications (LONIPCs)
- •Conclusion
- •References
- •Introduction
- •Pulmonary Hypertension Associated with Sarcoidosis (Group 5.2)
- •PH Associated with Pulmonary Langerhans Cell Histiocytosis (Group 5.2)
- •PH in Combined Pulmonary Fibrosis and Emphysema (Group 3.3)
- •PH Associated with Lymphangioleiomyomatosis (Group 3)
- •Hereditary Hemorrhagic Telangiectasia (Group 1.2)
- •Pulmonary Veno-Occlusive Disease (Group 1.5)
- •Small Patella Syndrome (Group 1.2)
- •Conclusion
- •References
- •Introduction
- •Epidemiology
- •Timing, Chronology, Delay Time
- •Route of Administration
- •Patterns of Involvement [3, 4]
- •Drugs and Agents Fallen Out of Favor
- •Drug-Induced Noncardiac Pulmonary Edema
- •Drug-Induced Cardiogenic Pulmonary Edema
- •The “Chemotherapy Lung”
- •Drug-Induced/Iatrogenic Alveolar Hemorrhage
- •Drugs
- •Superwarfarin Rodenticides
- •Transfusion Reactions: TACO–TRALI
- •Acute Eosinophilic Pneumonia
- •Acute Granulomatous Interstitial Lung Disease
- •Acute Organizing Pneumonia (OP), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), or Acute Fibrinous Organizing Pneumonia (AFOP) Patterns
- •Acute Amiodarone-Induced Pulmonary Toxicity (AIPT)
- •Accelerated Pulmonary Fibrosis
- •Acute Exacerbation of Previously Known (Idiopathic) Pulmonary Fibrosis
- •Anaphylaxis
- •Acute Vasculopathy
- •Drug-Induced/Iatrogenic Airway Emergencies
- •Airway Obstruction as a Manifestation of Anaphylaxis
- •Drug-Induced Angioedema
- •Hematoma Around the Upper Airway
- •The “Pill Aspiration Syndrome”
- •Catastrophic Drug-Induced Bronchospasm
- •Peri-operative Emergencies (Table 42.8)
- •Other Rare Presentations
- •Pulmonary Nodules and Masses
- •Pleuroparenchymal Fibroelastosis
- •Late Radiation-Induced Injury
- •Chest Pain
- •Rebound Phenomenon
- •Recall Pneumonitis
- •Thoracic Bezoars: Gossipybomas
- •Respiratory Diseases Considered Idiopathic That May Be Drug-Induced (Table 42.4)
- •Eye Catchers
- •Conclusion
- •References
- •Cancer Mimics of Organizing Pneumonia
- •Lung Adenocarcinoma/Bronchioloalveolar Carcinoma
- •Primary Pulmonary Lymphoma
- •Cancer Mimics of Interstitial Lung Diseases
- •Lymphangitic Carcinomatosis
- •Epithelioid Hemangio-Endothelioma
- •Lymphomatoid Granulomatosis
- •Cystic Tumors
- •Cavitating Tumors
- •Intrathoracic Pseudotumors
- •Respiratory Papillomatosis
- •Pulmonary Langerhans Cell Histiocytosis
- •References
- •Index
580 |
V. Cottin |
|
|
served spirometry, severe impairment of exercise capacity and gas exchange, exercise limitation mostly determined by the pulmonary vascular component of disease, right ventricular dysfunction, and/or severe PH.
Clinical Vignette
A 68-year-old male, ex-smoker, with a history of 48 pack-years of tobacco use, who had worked as a mason with no signi cant exposure to asbestos, was referred to the pulmonary clinic for severe dyspnea on exertion. He had a history of coronary heart disease, with myocardial infarction and coronary stenting 4 years prior to admission. Velcro-crackle rales of the lung bases were present at lung auscultation. The chest radiograph demonstrated mild hyperlucency of the upper zones, with hyperinfation, and reticular changes of the lower zones. Chest HRCT demonstrated both emphysema of the upper zones (centrilobular and paraseptal) andbrosis of the lung bases, with subpleural reticulation, honeycombing, and traction bronchiectasis, with non- prominent superimposed ground-glass attenuation (Fig. 33.5). Areas of admixed pulmonary brosis and emphysema were observed in the mid sections of the lungs. Emphysema extent on HRCT was visually quanti ed by an experienced radiologist and estimated to represent 15–20% of total lung volume. Pulmonary function tests were: FVC 86% of predicted value, FEV1 78% of predicted, FEV1:FVC 0.68, TLC 89%, RV 117%, DLco 44%, Kco 57%, PaO2 at rest 65 mmHg. Echocardiography showed slightly dilated right heart cavities with estimated systolic pulmonary artery pressure of 42 mmHg. No clinical signs of connective tissue disease were present, and antinuclear antibodies were negative. The patient was diagnosed with combined pulmonary brosis and emphysema syndrome at multidisciplinary discussion, with probable UIP pattern at HRCT, therefore corresponding to idiopathic pulmonary brosis combined with emphysema. Lung biopsy was not performed. Inhaled bronchodilators and an anti brotic therapy were initiated. Fourteen months later, he was readmitted for acute right heart failure. Right heart catheterization demonstrated severe precapillary pulmonary hypertension, with mean pulmonary artery pressure of 42 mmHg, pulmonary artery wedge pressure of 12 mmHg, and cardiac index of 1.9 L/min/m2. Sildena l was initiated in the setting of a prospective registry, with moderate hemodynamic improvement at 3 months, and unclear clinical bene t. The patient died of acute respiratory failure 5 months after the diagnosis of pulmonary hypertension.
References
1.\Robbins LL. Idiopathic pulmonary brosis: roentgenologic ndings. Radiology. 1948;51:459–67.
2.\Mallory TB, Castleman B, Parris EE. Case records of the Massachusetts general hospital. Case 34191. New Engl J Med. 1948;238:667–71.
3.\Wiggins J, Strickland B, Turner-Warwick M. Combined cryptogenic brosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med. 1990;84:365–9.
4.\Wells AU, King AD, Rubens MB, Cramer D, du Bois RM, Hansell DM. Lone cryptogenic brosing alveolitis: a functional- morphologic correlation based on extent of disease on thin- section computed tomography. Am J Respir Crit Care Med. 1997;155:1367–75.
5.\Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, Colby TV, du Bois RM, Hansell DM. Idiopathic pulmonarybrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167:962–9.
6.\Hiwatari N, Shimura S, Takishima T. Pulmonary emphysema followed by pulmonary brosis of undetermined cause. Respiration. 1993;60:354–8.
7.\Doherty MJ, Pearson MG, O’Grady EA, Pellegrini V, Calverley PM. Cryptogenic brosing alveolitis with preserved lung volumes. Thorax. 1997;52:998–1002.
8.\Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie- Leblond I, Israel-Biet D, Court-Fortune I, Valeyre D, Cordier JF. Combined pulmonary brosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26:586–93.
9.\Cordier JF, Cottin V. Neglected evidence in idiopathic pulmonary brosis: from history to earlier diagnosis. Eur Respir J. 2013;42:916–23.
10.\Balbi B, Cottin V, Singh S, De Wever W, Herth FJ, Robalo Cordeiro C. Smoking-related lung diseases: a clinical perspective. Eur Respir J. 2010;35:231–3.
11.\Girard N, Marchand Adam S, Naccache JM, Borie R, Urban T, Jouneau S, Marchand E, Ravel AC, Kiakouama L, Etienne- Mastroianni B, Cadranel J, Cottin V, Cordier JF. Lung cancer in combined pulmonary brosis and emphysema: a series of 47 Western patients. J Thorac Oncol. 2014;9:1162–70.
12.\Cottin V, Cordier JF. The syndrome of combined pulmonary brosis and emphysema. Chest. 2009;136:1–2.
13.\Ryerson CJ, Hartman T, Elicker BM, Ley B, Lee JS, Abbritti M, Jones KD, King TE Jr, Ryu J, Collard HR. Clinical features and outcomes in combined pulmonary brosis and emphysema in idiopathic pulmonary brosis. Chest. 2013;144:234–40.
14.\Tzouvelekis A, Zacharis G, Oikonomou A, Mikroulis D, Margaritopoulos G, Koutsopoulos A, Antoniadis A, Koulelidis A, Steiropoulos P, Boglou P, Bakali M, Froudarakis M, Bouros D. Increased incidence of autoimmune markers in patients with combined pulmonary brosis and emphysema. BMC Pulm Med. 2013;13:31.
15.\Akagi T, Matsumoto T, Harada T, Tanaka M, Kuraki T, Fujita M, Watanabe K. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary brosis. Respir Med. 2009;103:1209–15.
16.\Alsumrain M, De Giacomi F, Nasim F, Koo CW, Bartholmai BJ, Levin DL, Moua T. Combined pulmonary brosis and emphysema as a clinicoradiologic entity: characterization of presenting lung brosis and implications for survival. Respir Med. 2019;146:106–12.
17.\Antoniou KM, Walsh SL, Hansell DM, Rubens MR, Marten K, Tennant R, Hansel T, Desai SR, Siafakas NM, du Bois RM,
33 The Syndrome of Combined Pulmonary Fibrosis and Emphysema |
581 |
|
|
Wells AU. Smoking-related emphysema is associated with idiopathic pulmonary brosis and rheumatoid lung. Respirology. 2013;18:1191–6.
18.\Cottin V, Hansell DM, Sverzellati N, Weycker D, Antoniou KM, Atwood M, Oster G, Kirchgaessler KU, Collard HR, Wells AU. Effect of emphysema extent on serial lung function in patients with idiopathic pulmonary brosis. Am J Respir Crit Care Med. 2017;196:1162–71.
19.\Jacob J, Bartholmai BJ, Rajagopalan S, Karwoski R, Nair A, Walsh SLF, Barnett J, Cross G, Judge EP, Kokosi M, Renzoni E, Maher TM, Wells AU. Likelihood of pulmonary hypertension in patients with idiopathic pulmonary brosis and emphysema. Respirology. 2018;23:593–9.
20.\Kurashima K, Takayanagi N, Tsuchiya N, Kanauchi T, Ueda M, Hoshi T, Miyahara Y, Sugita Y. The effect of emphysema on lung function and survival in patients with idiopathic pulmonary brosis. Respirology. 2010;15:843–8.
21.\Mejia M, Carrillo G, Rojas-Serrano J, Estrada A, Suarez T, Alonso D, Barrientos E, Gaxiola M, Navarro C, Selman M. Idiopathic pulmonary brosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest. 2009;136:10–5.
22.\Tasaka S, Mizoguchi K, Funatsu Y, Namkoong H, Yamasawa W, Ishii M, Hasegawa N, Betsuyaku T. Cytokine pro le of bronchoalveolar lavage fuid in patients with combined pulmonary brosis and emphysema. Respirology. 2012;17:814.
23.\Sangani R, Ghio A, Culp S, Patel Z, Sharma S. Combined pulmonary brosis emphysema: role of cigarette smoking and pulmonary hypertension in a rural cohort. Int J Chron Obstruct Pulm Dis. 2021;16:1873–85.
24.\Jankowich MD, Rounds SIS. Combined pulmonary brosis and emphysema syndrome. A review. Chest. 2012;141:222–31.
25.\Cottin V, Le Pavec J, Prevot G, Mal H, Humbert M, Simonneau G, Cordier JF. Pulmonary hypertension in patients with combined pulmonary brosis and emphysema syndrome. Eur Respir J. 2010;35:105–11.
26.\Cottin V, Nunes H, Mouthon L, Gamondes D, Lazor R, Hachulla E, Revel D, Valeyre D, Cordier JF. Combined pulmonary brosis and emphysema syndrome in connective tissue disease. Arthritis Rheum. 2011;63:295–304.
27.\Hammond EC, Auerbach O, Kirman D, Gar nkel L. Effects of cigarette smoking on dogs. Arch Environ Health. 1970;21:740–53.
28.\Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary brosis. An integral model. Am J Respir Crit Care Med. 2014;189:1161–72.
29.\Selman M, Martinez FJ, Pardo A. Why does an aging smoker’s lung develop idiopathic pulmonary brosis and not chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2019;199:279–85.
30.\Drans eld MT, Washko GR, Foreman MG, Estepar RS, Reilly J, Bailey WC. Gender differences in the severity of CT emphysema in COPD. Chest. 2007;132:464–70.
31.\Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary brosis. Am J Respir Crit Care Med. 2006;174:810–6.
32.\King TE Jr, Pardo A, Selman M. Idiopathic pulmonary brosis. Lancet. 2011;378:1949–61.
33.\du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary brosis. Am J Respir Crit Care Med. 2011;184:459–66.
34.\Jacob J, Song JW, Yoon HY, Cross G, Barnett J, Woo WL, Adams F, Kokosi M, Devaraj A, Renzoni E, Maher TM, Kim DS, Wells AU. Prevalence and effects of emphysema in never-smokers with
rheumatoid arthritis interstitial lung disease. EBioMedicine. 2018;28:303–10.
35.\Antoniou KM, Margaritopoulos GA, Goh NS, Karagiannis K, Desai SR, Nicholson AG, Siafakas NM, Coghlan JG, Denton CP, Hansell DM, Wells AU. Combined pulmonary brosis and emphysema in scleroderma-related lung disease has a major confounding effect on lung physiology and screening for pulmonary hypertension. Arthritis Rheum. 2016;68:1004–12.
36.\Ariani A, Silva M, Bravi E, Parisi S, Saracco M, De Gennaro F, Caimmi C, Girelli F, De Santis M, Volpe A, Lumetti F, Hax V, Bredemeier M, Al eri V, Santilli D, Bodini FC, Lucchini G, Mozzani F, Seletti V, Bacchini E, Arrigoni E, Giuggioli D, Chakr R, Idolazzi L, Bertorelli G, Imberti D, Michieletti E, Paolazzi G, Fusaro E, Chetta AA, Scirè CA, Sverzellati N. Overall mortality in combined pulmonary brosis and emphysema related to systemic sclerosis. RMD Open. 2019;5:e000820.
37.\Cormier Y, Brown M, Worthy S, Racine G, Muller NL. High- resolution computed tomographic characteristics in acute farmer’s lung and in its follow-up. Eur Respir J. 2000;16:56–60.
38.\Erkinjuntti-Pekkanen R, Rytkonen H, Kokkarinen JI, Tukiainen HO, Partanen K, Terho EO. Long term risk of emphysema in patients with farmer’s lung and matched control farmers. Am J Respir Crit Care Med. 1998;158:662–5.
39.\Soumagne T, Pana-Katatali H, Degano B, Dalphin JC. Combined pulmonary brosis and emphysema in hypersensitivity pneumonitis. BMJ Case Rep. 2015;2015:bcr2015211560.
40.\Jacob J, Odink A, Brun AL, Macaluso C, de Lauretis A, Kokosi M, Devaraj A, Desai S, Renzoni E, Wells AU. Functional associations of pleuroparenchymal broelastosis and emphysema with hypersensitivity pneumonitis. Respir Med. 2018;138:95–101.
41.\Chilosi M, Poletti V, Rossi A. The pathogenesis of COPD and IPF: distinct horns of the same devil? Respir Res. 2012;13:3.
42.\Faner R, Rojas M, Macnee W, Agusti A. Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonarybrosis. Am J Respir Crit Care Med. 2012;186:306–13.
43.\Chilosi M, Carloni A, Rossi A, Poletti V. Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonarybrosis and COPD/emphysema. Transl Res. 2013;162:156–73.
44.\Alder JK, Guo N, Kembou F, Parry EM, Anderson CJ, Gorgy AI, Walsh MF, Sussan T, Biswal S, Mitzner W, Tuder RM, Armanios M. Telomere length is a determinant of emphysema susceptibility. Am J Respir Crit Care Med. 2011;184:904–12.
45.\Hisata S, Sakaguchi H, Kanegane H, Hidaka T, Ichinose M, Kojima S, Nukiwa T, Ebina M. A novel missense mutation of DKC1 in dyskeratosis congenita with pulmonary brosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30:221–5.
46.\Stanley SE, Chen JJ, Podlevsky JD, Alder JK, Hansel NN, Mathias RA, Qi X, Rafaels NM, Wise RA, Silverman EK, Barnes KC, Armanios M. Telomerase mutations in smokers with severe emphysema. J Clin Invest. 2015;125:563–70.
47.\Nunes H, Monnet I, Kannengiesser C, Uzunhan Y, Valeyre D, Kambouchner M, Naccache JM. Is telomeropathy the explanation for combined pulmonary brosis and emphysema syndrome? Report of a family with TERT mutation. Am J Respir Crit Care Med. 2014;189:753–4.
48.\Newton CA, Batra K, Torrealba J, Kozlitina J, Glazer CS, Aravena C, Meyer K, Raghu G, Collard HR, Garcia CK. Telomere-related lung brosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J. 2016;48:1710–20.
49.\Cottin V, Reix P, Khouatra C, Thivolet-Bejui F, Feldmann D, Cordier JF. Combined pulmonary brosis and emphysema syndrome associated with familial SFTPC mutation. Thorax. 2011;66:918–9.
50.\Epaud R, Delestrain C, Louha M, Simon S, Fanen P, Tazi A. Combined pulmonary brosis and emphysema syndrome associated with ABCA3 mutations. Eur Respir J. 2014;43:638–41.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
582 |
V. Cottin |
|
|
51.\Cottin V, Cordier JF. SFTPC mutations in patients with familial pulmonary brosis: combined with emphysema? Am J Respir Crit Care Med. 2011;183:1113; author reply 1113–1114.
52.\van Moorsel CH, van Oosterhout MF, Barlo NP, de Jong PA, van der Vis JJ, Ruven HJ, van Es HW, van den Bosch JM, Grutters JC. Surfactant protein C mutations are the basis of a signi cant portion of adult familial pulmonary brosis in a Dutch cohort. Am J Respir Crit Care Med. 2010;182:1419–25.
53.\Ota C, Kimura M, Kure S. ABCA3 mutations led to pulmonarybrosis and emphysema with pulmonary hypertension in an 8-year-old girl. Pediatr Pulmonol. 2016;51:E21–3.
54.\Glasser SW, Detmer EA, Ikegami M, Na CL, Stahlman MT, Whitsett JA. Pneumonitis and emphysema in sp-C gene targeted mice. J Biol Chem. 2003;278:14291–8.
55.\Stanley SE, Gable DL, Wagner CL, Carlile TM, Hanumanthu VS, Podlevsky JD, Khalil SE, DeZern AE, Rojas-Duran MF, Applegate CD, Alder JK, Parry EM, Gilbert WV, Armanios M. Loss-of-function mutations in the RNA biogenesis factor NAF1 predispose to pulmonary brosis-emphysema. Sci Transl Med. 2016;8:351ra107.
56.\Cottin V, Nasser M, Traclet J, Chalabreysse L, Lebre AS, Si-Mohamed S, Philit F, Thivolet-Bejui F. Prolidase de ciency: a new genetic cause of combined pulmonary brosis and emphysema syndrome in the adult. Eur Respir J. 2020;55:1901952.
57.\Kukkonen MK, Tiili E, Vehmas T, Oksa P, Piirila P, Hirvonen A. Association of genes of protease-antiprotease balance pathway to lung function and emphysema subtypes. BMC Pulm Med. 2013;13:36.
58.\Gu H, You H, Ning W, Zhou H, Wang J, Lu Y, Sun J, Kou Y, Dong H. Internal migration and maternal health service utilisation in Jiangsu, China. Trop Med Int Health. 2017;22:124–32.
59.\Xu L, Bian W, Gu XH, Shen C. Genetic polymorphism in matrix metalloproteinase-9 and transforming growth factor-beta1 and susceptibility to combined pulmonary brosis and emphysema in a Chinese population. Kaohsiung J Med Sci. 2017;33:124–9.
60.\Kinjo T, Kitaguchi Y, Droma Y, Yasuo M, Wada Y, Ueno F, Ota M, Hanaoka M. The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary brosis in combined pulmonarybrosis and emphysema (CPFE) in Japanese patients. Sci Rep. 2020;10:12811.
61.\Guzmán-Vargas J, Ambrocio-Ortiz E, Pérez-Rubio G, Ponce- Gallegos MA, Hernández-Zenteno RJ, Mejía M, Ramírez- Venegas A, Buendia-Roldan I, Falfán-Valencia R. Differential genomic pro le in TERT, DSP, and FAM13A between COPD patients with emphysema, IPF, and CPFE syndrome. Front Med. 2021;8:725144.
62.\Warburton D, Shi W, Xu B. TGF-beta-Smad3 signaling in emphysema and pulmonary brosis: an epigenetic aberration of normal development? Am J Physiol Lung Cell Mol Physiol. 2013;304:L83–5.
63.\Armanios M. Telomerase makes connections between pulmonary brosis and emphysema. Am J Respir Crit Care Med. 2014;189:754–5.
64.\Ryu JH, Parambil JG, McGrann PS, Aughenbaugh GL. Lack of evidence for an association between neuro bromatosis and pulmonary brosis. Chest. 2005;128:2381–6.
65.\Cottin V, Cordier JF. Combined pulmonary brosis and emphysema in connective tissue disease. Curr Opin Pulm Med. 2012;18:418–27.
66.\Hwang J-H, Misumi S, Sahin H, Brown KK, Newell JD, Lynch DA. Computed tomographic features of idiopathic brosing interstitial pneumonia: comparison with pulmonary brosis related to collagen vascular disease. J Comput Assist Tomogr. 2009;33:410–5.
67.\Song JW, Do K-H, Kim M-Y, Jang SJ, Colby TV, Kim DS. Pathologic and radiologic differences between idiopathic and
collagen vascular disease-related usual interstitial pneumonia. Chest. 2009;136:23–30.
68.\Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax. 2001;56:622–7.
69.\Tanaka N, Kim JS, Newell JD, Brown KK, Cool CD, Meehan R, Emoto T, Matsumoto T, Lynch DA. Rheumatoid arthritis-related lung diseases: CT ndings. Radiology. 2004;232:81–91.
70.\Kallberg H, Ding B, Padyukov L, Bengtsson C, Ronnelid J, Klareskog L, Alfredsson L. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis. 2011;70:508–11.
71.\Klareskog L, Ronnelid J, Lundberg K, Padyukov L, Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol. 2008;26:651–75.
72.\Spagnolo P, Grunewald J, du Bois RM. Genetic determinants of pulmonary brosis: evolving concepts. Lancet Respir Med. 2014;2:416–28.
73.\Albano SA, Santana-Sahagun E, Weisman MH. Cigarette smoking and rheumatoid arthritis. Semin Arthritis Rheum. 2001;31:146–59.
74.\Turesson C, O’Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003;62:722–7.
75.\Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc. 2007;4:443–8.
76.\Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009;136:1397–405.
77.\Wendling D, Vidon C, Godfrin-Valnet M, Rival G, Guillot X, Prati C. Exacerbation of combined pulmonary brosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis. Joint Bone Spine. 2013;80:670–1.
78.\Cottin V, Fabien N, Khouatra C, Moreira A, Cordier JF. Anti- elastin autoantibodies are not present in combined pulmonarybrosis and emphysema. Eur Respir J. 2009;33:219–21.
79.\Desai SR, Veeraraghavan S, Hansell DM, Nikolakopolou A, Goh NSL, Nicholson AG, Colby TV, Denton CP, Black CM, du Bois RM, Wells AU. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary brosis and nonspeci c interstitial pneumonia. Radiology. 2004;232:560–7.
80.\Hudson M, Lo E, Lu Y, Hercz D, Baron M, Steele R. Cigarette smoking in patients with systemic sclerosis. Arthritis Rheum. 2011;63:230–8.
81.\Champtiaux N, Cottin V, Chassagnon G, Chaigne B, Valeyre D, Nunes H, Hachulla E, Launay D, Crestani B, Cazalets C, Jego P, Bussone G, BerezneA, Guillevin L, Revel MP, Cordier JF, Mouthon L, Groupe d’Etudes et de Recherche sur les Maladies Orphelines Pulmonaires. Combined pulmonary brosis and emphysema in systemic sclerosis: a syndrome associated with heavy morbidity and mortality. Semin Arthritis Rheum. 2019;49:98–104.
82.\Yamakawa H, Takemura T, Iwasawa T, Yamanaka Y, Ikeda S, Sekine A, Kitamura H, Baba T, Iso S, Okudela K, Kuwano K, Ogura T. Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy? BMC Pulm Med. 2018;18:25.
83.\Bae SS, Pourzand L, Kim GH, Villegas BE, Oh A, Furst DE, Goldin J, Tashkin DP. The disconnect between visual assessment of air trapping and lung physiology for assessment of small airway disease in scleroderma-related interstitial lung disease: an observation from the Scleroderma Lung Study II Cohort. J Scleroderma Relat Disord. 2021;7:117.
84.\Cottin V, Freymond N, Cabane J, Cordier JF. Combined pulmonary brosis and emphysema syndrome in a patient age 28 years with severe systemic sclerosis. J Rheumatol. 2011;38:2082–3.
33 The Syndrome of Combined Pulmonary Fibrosis and Emphysema |
583 |
|
|
85.\Lubatti C, Zeni S, Ingegnoli F. Combined pulmonary brosis and emphysema syndrome in systemic sclerosis. Int J Rheum Dis. 2012;15:e122–3.
86.\Szapiel SV, Fulmer JD, Hunninghake GW, Elson NA, Kawanami O, Ferrans VJ, Crystal RG. Hereditary emphysema in the tight- skin (Tsk/+) mouse. Am Rev Respir Dis. 1981;123:680–5.
87.\Martorana PA, Wilkinson M, van Even P, Lungarella G. Tsk mice with genetic emphysema. Right ventricular hypertrophy occurs without hypertrophy of muscular pulmonary arteries or muscularization of arterioles. Am Rev Respir Dis. 1990;142:333–7.
88.\Cottin V, Cordier JF. Combined pulmonary brosis and emphysema: an experimental and clinically relevant phenotype. Am J Respir Crit Care Med. 2005;172:1605; author reply 1605–1606.
89.\Wert SE, Yoshida M, LeVine AM, Ikegami M, Jones T, Ross GF, Fisher JH, Korfhagen TR, Whitsett JA. Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice. Proc Natl Acad Sci U S A. 2000;97:5972–7.
90.\Lundblad LK, Thompson-Figueroa J, Leclair T, Sullivan MJ, Poynter ME, Irvin CG, Bates JH. Tumor necrosis factor-alpha overexpression in lung disease: a single cause behind a complex phenotype. Am J Respir Crit Care Med. 2005;171:1363–70.
91.\Lucatelli M, Bartalesi B, Cavarra E, Fineschi S, Lunghi B, Martorana PA, Lungarella G. Is neutrophil elastase the missing link between emphysema and brosis? Evidence from two mouse models. Respir Res. 2005;6:83.
92.\Couillin I, Vasseur V, Charron S, Gasse P, Tavernier M, Guillet J, Lagente V, Fick L, Jacobs M, Coelho FR, Moser R, Ryffel B. IL-1R1/MyD88 signaling is critical for elas- tase-induced lung infammation and emphysema. J Immunol. 2009;183:8195–202.
93.\Lappalainen U, Whitsett JA, Wert SE, Tichelaar JW, Bry K. Interleukin-1beta causes pulmonary infammation, emphysema, and airway remodeling in the adult murine lung. Am J Respir Cell Mol Biol. 2005;32:311–8.
94.\Samara KD, Margaritopoulos G, Wells AU, Siafakas NM, Antoniou KM. Smoking and pulmonary brosis: novel insights. Pulm Med. 2011;2011:461439.
95.\Lakhanpal S, Lie JT, Conn DL, Martin WJ II. Pulmonary disease in polymyositis/dermatomyositis: a clinicopathological analysis of 65 autopsy cases. Ann Rheum Dis. 1987;46:23–9.
96.\Harel-Meir M, Sherer Y, Shoenfeld Y. Tobacco smoking and autoimmune rheumatic diseases. Nat Clin Pract Rheumatol. 2007;3:707–15.
97.\Corte TJ, Copley SJ, Desai SR, Zappala CJ, Hansell DM, Nicholson AG, Colby TV, Renzoni E, Maher TM, Wells AU. Signi cance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J. 2012;39:661–8.
98.\Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest. 2011;140:1292–9.
99.\Fischer A, West SG, Swigris JJ, Brown KK, du Bois RM. Connective tissue disease-associated interstitial lung disease: a call for clari cation. Chest. 2010;138:251–6.
100.\Cottin V. Signi cance of connective tissue disease features in pulmonary brosis. Eur Respir Rev. 2013;122:273–80.
101.\Fischer A, Solomon JJ, du Bois RM, Deane KD, Olson AL, Fernandez-Perez ER, Huie TJ, Stevens AD, Gill MB, Rabinovitch AM, Lynch DA, Burns DA, Pineiro IS, Groshong SD, Duarte Achcar RD, Brown KK, Martin RJ, Swigris JJ. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med. 2012;106:1040–7.
102.\Tzouvelekis A, Zacharis G, Oikonomou A, Koulelidis A, Steiropoulos P, Froudarakis M, Kriki P, Vargemezis V, Bouros D. Combined pulmonary brosis and emphysema associated with microscopic polyangiitis. Eur Respir J. 2012;40:505–7.
103.\Gocho K, Sugino K, Sato K, Hasegawa C, Uekusa T, Homma S. Microscopic polyangiitis preceded by combined pulmonarybrosis and emphysema. Respir Med Case Rep. 2015;15:128–32.
104.\Silva DR, Gazzana MB, Barreto SSM, Knorst MM. Idiopathic pulmonary brosis and emphysema in smokers. J Bras Pneumol. 2008;34:779–86.
105.\Zhang M, Yoshizawa A, Kawakami S, Asaka S, Yamamoto H, Yasuo M, Agatsuma H, Toishi M, Shiina T, Yoshida K, Honda T, Ito KI. The histological characteristics and clinical outcomes of lung cancer in patients with combined pulmonary brosis and emphysema. Cancer Med. 2016;5:2721–30.
106.\Ye Q, Huang K, Ding Y, Lou B, Hou Z, Dai H, Wang C. Cigarette smoking contributes to idiopathic pulmonary brosis associated with emphysema. Chin Med J. 2014;127:469–74.
107.\Tokgoz Akyıl F, Sevim T, Akman C, Aksoy E, Ağca M, Aktas O, Akyıl M. The predictors of mortality in IPF - does emphysema change the prognosis? Sarcoidosis Vasc Diffuse Lung Dis. 2016;33:267–74.
108.\Portillo K, Perez-Rodas N, Garcia-Olive I, Guasch-Arriaga I, Centeno C, Serra P, Becker-Lejuez C, Sanz-Santos J, Andreo Garcia F, Ruiz-Manzano J. Lung cancer in patients with combined pulmonary brosis and emphysema and idiopathic pulmonary brosis. A descriptive study in a Spanish series. Arch Bronconeumol. 2017;53:304–10.
109.\Otsuka H, Sugino K, Hata Y, Makino T, Koezuka S, Isobe K, Tochigi N, Shibuya K, Homma S, Iyoda A. Clinical features and outcomes of patients with lung cancer as well as combined pulmonary brosis and emphysema. Mol Clin Oncol. 2016;5:273–8.
110.\Fukui M, Suzuki K, Matsunaga T, Oh S, Takamochi K. Outcomes of lung cancer resection for patients with combined pulmonarybrosis and emphysema. Surg Today. 2016;46:341–7.
111.\Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Maher TM, Nair A, Karwoski R, Renzoni E, Walsh SLF, Hansell DM, Wells AU. Functional and prognostic effects when emphysema complicates idiopathic pulmonary brosis. Eur Respir J. 2017;50:1700379.
112.\Kim YJ, Shin SH, Park JW, Kyung SY, Kang SM, Lee SP, Sung YM, Kim YK, Jeong SH. Annual change in pulmonary function and clinical characteristics of combined pulmonary brosis and emphysema and idiopathic pulmonary brosis: over a 3-year fol- low-up. Tuberc Respir Dis. 2014;77:18–23.
113.\Chae KJ, Jin GY, Jung HN, Kwon KS, Choi H, Lee YC, Chung MJ, Park HS. Differentiating Smoking-Related Interstitial Fibrosis (SRIF) from Usual Interstitial Pneumonia (UIP) with emphysema using ct features based on pathologically proven cases. PLoS One. 2016;11:e0162231.
114.\Nemoto M, Noma S, Otsuki A, Nakashima K, Honma K, Johkoh T, Fukuoka J, Aoshima M. Combined pulmonary brosis and emphysema with myeloperoxidase-antineutrophil cytoplasmic antibody positivity that resolved upon smoking cessation. Respir Med Case Rep. 2018;25:165–9.
115.\Alba DB, Suárez SR, Morillo SG. Relationship between combination of pulmonary brosis and emphysema, ANCA, and vasculitis. Chest. 2020;158:1288–9.
116.\Leigh J, Driscoll TR, Cole BD, Beck RW, Hull BP, Yang J. Quantitative relation between emphysema and lung mineral content in coal workers. Occup Environ Med. 1994;51:400–7.
117.\Heppleston AG. The pathological recognition and pathogenesis of emphysema and brocystic disease of the lung with special reference to coal workers. Ann N Y Acad Sci. 1972;200:347–69.
118.\Akira M, Yamamoto S, Inoue Y, Sakatani M. High-resolution CT of asbestosis and idiopathic pulmonary brosis. AJR Am J Roentgenol. 2003;181:163–9.
119.\Copley SJ, Wells AU, Sivakumaran P, Rubens MB, Lee YCG, Desai SR, MacDonald SLS, Thompson RI, Colby TV, Nicholson
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
584 |
V. Cottin |
|
|
AG, du Bois RM, Musk AW, Hansell DM. Asbestosis and idiopathic pulmonary brosis: comparison of thin-section CT features. Radiology. 2003;229:731–6.
120.\Copley SJ, Lee YC, Hansell DM, Sivakumaran P, Rubens MB, Newman Taylor AJ, Rudd RM, Musk AW, Wells AU. Asbestos- induced and smoking-related disease: apportioning pulmonary function de cit by using thin-section CT. Radiology. 2007;242:258–66.
121.\Huuskonen O, Kivisaari L, Zitting A, Kaleva S, Vehmas T. Emphysema ndings associated with heavy asbestos-exposure in high resolution computed tomography of Finnish construction workers. J Occup Health. 2004;46:266–71.
122.\Begin R, Filion R, Ostiguy G. Emphysema in silicaand asbestos- exposed workers seeking compensation. A CT scan study. Chest. 1995;108:647–55.
123.\Daniil Z, Koutsokera A, Gourgoulianis K. Combined pulmonarybrosis and emphysema in patients exposed to agrochemical compounds. Eur Respir J. 2006;27:434.
124.\Marchiori E, Lourenco S, Gasparetto TD, Zanetti G, Mano CM, Nobre LF. Pulmonary talcosis: imaging ndings. Lung. 2010;188:165–71.
125.\Karkhanis VS, Joshi JM. Combined pulmonary brosis and emphysema in a tyre industry worker. Lung India. 2012;29:273–6.
126.\Porru S, Placidi D, Quarta C, Sabbioni E, Pietra R, Fortaner S. The potencial role of rare earths in the pathogenesis of interstitial lung disease: a case report of movie projectionist as investigated by neutron activation analysis. J Trace Elem Med Biol. 2001;14:232–6.
127.\Roshan R, Guptal M, Kulshrestha R, Menon B, Chhabra SK. Combined pulmonary brosis and emphysema in a welder. Monaldi Arch Chest Dis. 2012;77:26–8.
128.\Antin-Ozerkis D, Rubinowitz A, Evans J, Homer RJ, Matthay RA. Interstitial lung disease in the connective tissue diseases. Clin Chest Med. 2012;33:123–49.
129.\Jankowich MD, Rounds S. Combined pulmonary brosis and emphysema alters physiology but has similar mortality to pulmonary brosis without emphysema. Lung. 2010;188:365–73.
130.\Kitaguchi Y, Fujimoto K, Hanaoka M, Kawakami S, Honda T, Kubo K. Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology. 2010;15:265–71.
131.\Mura M, Zompatori M, Pacilli AM, Fasano L, Schiavina M, Fabbri M. The presence of emphysema further impairs physiologic function in patients with idiopathic pulmonary brosis. Respir Care. 2006;51:257–65.
132.\Schmidt SL, Nambiar AM, Tayob N, Sundaram B, Han MK, Gross BH, Kazerooni EA, Chughtai AR, Lagstein A, Myers JL, Murray S, Toews GB, Martinez FJ, Flaherty KR. Pulmonary function measures predict mortality differently in IPF versus combined pulmonary brosis and emphysema. Eur Respir J. 2011;38:176–83.
133.\Grubstein A, Bendayan D, Schactman I, Cohen M, Shitrit D, Kramer MR. Concomitant upper-lobe bullous emphysema, lower- lobe interstitial brosis and pulmonary hypertension in heavy smokers: report of eight cases and review of the literature. Respir Med. 2005;99:948–54.
134.\Behr J. Disease progression in idiopathic pulmonary brosis. FVC is not enough. Am J Respir Crit Care Med. 2017;196:1094–5.
135.\Kitaguchi Y, Fujimoto K, Hanaoka M, Honda T, Hotta J, Hirayama J. Pulmonary function impairment in patients with combined pulmonary brosis and emphysema with and without airfow obstruction. Int J Chron Obstruct Pulm Dis. 2014;9:805–11.
136.\Wells AU, Margaritopoulos GA, Antoniou KM, Nunes H, Costabel U. CPFE: distinctive and non-distinctive features. Eur Respir Monogr. 2016;71:175–85.
137.\Çiftci F, Gülpınar B, Atasoy Ç, Kayacan O, Saryal S. Combined pulmonary brosis and emphysema: how does cohabitation affect respiratory functions? Adv Med Sci. 2019;64:285–91.
138.\Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, Ross JC, Estepar RS, Lynch DA, Brehm JM, Andriole KP, Diaz AA, Khorasani R, D’Aco K, Sciurba FC, Silverman EK, Hatabu H, Rosas IO. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med. 2011;364:897–906.
139.\Bodlet A, Maury G, Jamart J, Dahlqvist C. Infuence of radiological emphysema on lung function test in idiopathic pulmonarybrosis. Respir Med. 2013;107:1781–8.
140.\Matsuoka S, Yamashiro T, Matsushita S, Kotoku A, Fujikawa A, Yagihashi K, Nakajima Y. Quantitative CT evaluation in patients with combined pulmonary brosis and emphysema: correlation with pulmonary function. Acad Radiol. 2015;22:626–31.
141.\Ando K, Sekiya M, Tobino K, Takahashi K. Relationship between quantitative CT metrics and pulmonary function in combined pulmonary brosis and emphysema. Lung. 2013;191:585–91.
142.\Yoon HY, Kim TH, Seo JB, Lee SM, Lim S, Lee HN, Kim N, Han M, Kim DS, Song JW. Effects of emphysema on physiological and prognostic characteristics of lung function in idiopathic pulmonary brosis. Respirology. 2019;24:55–62.
143.\Ash SY, Harmouche R, Ross JC, Diaz AA, Rahaghi FN, Vegas Sanchez-Ferrero G, Putman RK, Hunninghake GM, Onieva Onieva J, Martinez FJ, Choi AM, Bowler RP, Lynch DA, Hatabu H, Bhatt SP, Drans eld MT, Wells JM, Rosas IO, San Jose Estepar R, Washko GR, Investigators CO. Interstitial features at chest CT enhance the deleterious effects of emphysema in the COPD gene cohort. Radiology. 2018;288:600–9.
144.\Lai RS, Chen CF, Chu KA, Lin MH. The effect of emphysema on survival in patients with idiopathic pulmonary brosis: a retrospective study in Taiwan. J Chin Med Assoc. 2019;82:922–8.
145.\Ponçot-Mongars R, Zysman M, Regent D, Gomez E, Chaouat A, Chabot F. Syndrome emphysème - fibrose pulmonaire: histoire naturelle de la maladie. Evolution chronologique clinique, fonctionnelle respiratoire et scanographique [Combined pulmonary fibrosis and emphysema: the natural history of the disease. The chronological evolution of clinical features, respiratory function and the CT scan]. Rev Mal Respir. 2013;30:222–6.
146.\Kitaguchi Y, Fujimoto K, Hayashi R, Hanaoka M, Honda T, Kubo K. Annual changes in pulmonary function in combined pulmonary brosis and emphysema: over a 5-year follow-up. Respir Med. 2013;107:1986–92.
147.\Brillet P, Cottin V, Letoumelin P, Landino F, Brauner M, Valeyre D, Cordier J, Nunes H. Syndrome emphysème des sommets etbrose pulmonaire des bases combinés (syndrome emphysème/brose): aspects tomodensitométriques et fonctionnels [Combined apical emphysema and basal brosis syndrome (emphysema/brosis syndrome): CT imaging features and pulmonary function tests]. J Radiol. 2009; 90: 43–51.
148.\Mori K, Shirai T, Mikamo M, Shishido Y, Akita T, Morita S, Asada K, Fujii M, Hozumi H, Suda T, Chida K. Respiratory mechanics measured by forced oscillation technique in combined pulmonary brosis and emphysema. Respir Physiol Neurobiol. 2013;185:235–40.
149.\Aduen JF, Zisman DA, Mobin SI, Venegas C, Alvarez F, Biewend M, Jolles HI, Keller CA. Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease. Mayo Clin Proc. 2007;82:48–54.
150.\Kiakouama L, Cottin V, Glerant JC, Bayle JY, Mornex JF, Cordier JF. Conditions associated with severe carbon monoxide diffusion coef cient reduction. Respir Med. 2011;105:1248–56.
151.\Kishaba T, Shimaoka Y, Fukuyama H, Yoshida K, Tanaka M, Yamashiro S, Tamaki H. A cohort study of mortality predictors and characteristics of patients with combined pulmonary brosis and emphysema. BMJ Open. 2012;2:e000988.
33 The Syndrome of Combined Pulmonary Fibrosis and Emphysema |
585 |
|
|
152.\Hansell DM, Bankier AA, Macmahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246:697.
153.\Lynch DA, Austin JH, Hogg JC, Grenier PA, Kauczor HU, Bankier AA, Barr RG, Colby TV, Galvin JR, Gevenois PA, Coxson HO, Hoffman EA, Newell JD Jr, Pistolesi M, Silverman EK, Crapo JD. CT-de nable subtypes of chronic obstructive pulmonary disease: a statement of the Fleischner Society. Radiology. 2015;277:192–205.
154.\Jankowich MD, Polsky M, Klein M, Rounds S. Heterogeneity in combined pulmonary brosis and emphysema. Respiration. 2008;75:411–7.
155.\Rogliani P, Mura M, Mattia P, Ferlosio A, Farinelli G, Mariotta S, Graziano P, Pezzuto G, Ricci A, Saltini C, Orlandi A. HRCT and histopathological evaluation of brosis and tissue destruction in IPF associated with pulmonary emphysema. Respir Med. 2008;102:1753–61.
156.\Marten K, Milne D, Antoniou KM, Nicholson AG, Tennant RC, Hansel TT, Wells AU, Hansell DM. Non-speci c interstitial pneumonia in cigarette smokers: a CT study. Eur Radiol. 2009;19:1679.
157.\Akira M, Inoue Y, Kitaichi M, Yamamoto S, Arai T, Toyokawa K. Usual interstitial pneumonia and nonspeci c interstitial pneumonia with and without concurrent emphysema: thin-section CTndings. Radiology. 2009;251:271–9.
158.\Inomata M, Ikushima S, Awano N, Kondoh K, Satake K, Masuo M, Kusunoki Y, Moriya A, Kamiya H, Ando T, Yanagawa N, Kumasaka T, Ogura T, Sakai F, Azuma A, Gemma A, Takemura T. An autopsy study of combined pulmonary brosis and emphysema: correlations among clinical, radiological, and pathological features. BMC Pulm Med. 2014;14:104.
159.\Suki B, Majumdar A, Parameswaran H, Cottin V, Cordier JF, Davis G, Bates JH. A network model of combined pulmonary emphysema and brosis: effects of gravity. Am J Respir Crit Care Med. 2009;179:A5938. (abstract).
160.\Smith BM, Austin JH, Newell JD Jr, D’Souza BM, Rozenshtein A, Hoffman EA, Ahmed F, Barr RG. Pulmonary emphysema subtypes on computed tomography: the MESA COPD study. Am J Med. 2014;127(94):e97–23.
161.\Sugiura H, Takeda A, Hoshi T, Kawabata Y, Sayama K, Jinzaki M, Kuribayashi S. Acute exacerbation of usual interstitial pneumonia after resection of lung cancer. Ann Thorac Surg. 2012;93:937–43.
162.\Watadani T, Sakai F, Johkoh T, Noma S, Akira M, Fujimoto K, Bankier AA, Lee KS, Muller NL, Song JW, Park JS, Lynch DA, Hansell DM, Remy-Jardin M, Franquet T, Sugiyama Y. Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology. 2013;266:936–44.
163.\Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendia-Roldan I, Selman M, Travis WD, Walsh S, Wilson KC, American Thoracic Society ERSJRS, Latin American Thoracic S. Diagnosis of Idiopathic Pulmonary Fibrosis. An of - cial ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–68.
164.\Oliva IB, Cortopassi F, Rochester CL, Rubinowitz AN. Combined pulmonary brosis and emphysema syndrome: a radiologic perspective. Monaldi Arch Chest Dis. 2011;75:220–34.
165.\Hatabu H, Hunninghake GM, Richeldi L, Brown KK, Wells AU, Remy-Jardin M, Verschakelen J, Nicholson AG, Beasley MB, Christiani DC, San Jose Estepar R, Seo JB, Johkoh T, Sverzellati N, Ryerson CJ, Graham Barr R, Goo JM, Austin JHM, Powell CA, Lee KS, Inoue Y, Lynch DA. Interstitial lung abnormalities detected incidentally on CT: a position paper from the Fleischner Society. Lancet Respir Med. 2020;8:726–37.
166.\Awano N, Inomata M, Ikushima S, Yamada D, Hotta M, Tsukuda S, Kumasaka T, Takemura T, Eishi Y. Histological analysis of vasculopathy associated with pulmonary hypertension in combined pulmonary brosis and emphysema: comparison with idiopathic pulmonary brosis or emphysema alone. Histopathology. 2017;70:896–905.
167.\KinoshitaY,Watanabe K, Ishii H, Kushima H, Fujita M, Nabeshima K. Distribution of emphysema and brosis in idiopathic pulmonary brosis with coexisting emphysema. Histopathology. 2019;74:1103–8.
168.\American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classi cation of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277–304.
169.\Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D. An of cial American Thoracic Society/ European Respiratory Society statement: update of the international multidisciplinary classi cation of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–48.
170.\Yousem SA. Respiratory bronchiolitis-associated interstitial lung disease with brosis is a lesion distinct from brotic nonspeci c interstitial pneumonia: a proposal. Mod Pathol. 2006;19:1474–9.
171.\Vlahovic G, Russell ML, Mercer RR, Crapo JD. Cellular and connective tissue changes in alveolar septal walls in emphysema. Am J Respir Crit Care Med. 1999;160:2086–92.
172.\Katzenstein AL, Mukhopadhyay S, Zanardi C, Dexter E. Clinically occult interstitial brosis in smokers: classi cation and signi cance of a surprisingly common nding in lobectomy specimens. Hum Pathol. 2010;41:316–25.
173.\Wright JL, Tazelaar HD, Churg A. Fibrosis with emphysema. Histopathology. 2011;58:517–24.
174.\Katzenstein AL. Smoking-related interstitial brosis (SRIF): pathologic ndings and distinction from other chronic brosing lung diseases. J Clin Pathol. 2013;66:882–7.
175.\Kawabata Y, Hoshi E, Murai K, Ikeya T, Takahashi N, Saitou Y, Kurashima K, Ubukata M, Takayanagi N, Sugita H, Kanauchi S, Colby TV. Smoking-related changes in the background lung of specimens resected for lung cancer: a semiquantitative study with correlation to postoperative course. Histopathology. 2008;53:707–14.
176.\Myers JL, Veal CF Jr, Shin MS, Katzenstein AL. Respiratory bronchiolitis causing interstitial lung disease. A clinicopathologic study of six cases. Am Rev Respir Dis. 1987;135:880–4.
177.\Yamada T, Nakanishi Y, Homma T, Uehara K, Mizutani T, Hoshi E, Shimizu Y, Kawabata Y, Colby TV. Airspace enlargement with brosis shows characteristic histology and immunohistology different from usual interstitial pneumonia, nonspeci c interstitial pneumonia and centrilobular emphysema. Pathol Int. 2013;63:206–13.
178.\Rabeyrin M, Thivolet F, Ferretti GR, Chalabreysse L, Jankowski A, Cottin V, Pison C, Cordier JF, Lantuejoul S. Usual interstitial pneumonia end-stage features from explants with radiologic and pathological correlations. Ann Diagn Pathol. 2015;19:269–76.
179.\Reddy TL, Mayo J, Churg A. Respiratory bronchiolitis with brosis. High-resolution computed tomography ndings and correlation with pathology. Ann Am Thorac Soc. 2013;10:590–601.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
586 |
V. Cottin |
|
|
180.\Wong AW, Liang J, Cottin V, Ryerson CJ. Diagnostic features in combined pulmonary brosis and emphysema: a systematic review. Ann Am Thorac Soc. 2020;17:1333–6.
181.\Kwak N, Park CM, Lee J, Park YS, Lee SM, Yim JJ, Yoo CG, Kim YW, Han SK, Lee CH. Lung cancer risk among patients with combined pulmonary brosis and emphysema. Respir Med. 2014;108:524–30.
182.\Moon SW, Park MS, Kim YS, Jang J, Lee JH, Lee C-T, Chung J-H, Shim HS, Lee KW, Kim S-S, Lee SH, Yoon HI. Combined pulmonary brosis and emphysema and idiopathic pulmonarybrosis in non-small cell lung cancer: impact on survival and acute exacerbation. BMC Polm. 2019;19:177.
183.\Nasim F, Moua T. Lung cancer in combined pulmonary brosis and emphysema: a large retrospective cohort analysis. ERJ Open Res. 2020;6:00521.
184.\Minegishi Y, Kokuho N, Miura Y, Matsumoto M, Miyanaga A, Noro R, Saito Y, Seike M, Kubota K, Azuma A, Kida K, Gemma A. Clinical features, anti-cancer treatments and outcomes of lung cancer patients with combined pulmonary brosis and emphysema. Lung Cancer. 2014;85:258–63.
185.\King TE Jr. Smoking and subclinical interstitial lung disease. N Engl J Med. 2011;364:968–70.
186.\Tsushima K, Sone S, Yoshikawa S, Yokoyama T, Suzuki T, Kubo K. The radiological patterns of interstitial change at an early phase: over a 4-year follow-up. Respir Med. 2010;104:1712–21.
187.\Chiba S, Ohta H, Abe K, Hisata S, Ohkouchi S, Hoshikawa Y, Kondo T, Ebina M. The diagnostic value of the interstitial biomarkers KL-6 and SP-D for the degree of brosis in combined pulmonary brosis and emphysema. Pulmon Med. 2012;2012:492960.
188.\Todd NW, Jeudy J, Lavania S, Franks TJ, Galvin JR, Deepak J, Britt EJ, Atamas SP. Centrilobular emphysema combined with pulmonary brosis results in improved survival. Fibrogenesis Tissue Repair. 2011;4:6.
189.\Cottin V, Cordier JF, Wells AU. Centrilobular emphysema combined with pulmonary brosis results in improved survival: a response. Fibrogenesis Tissue Repair. 2011;4:16.
190.\Lee CH, Kim HJ, Park CM, Lim KY, Lee JY, Kim DJ, Yeon JH, Hwang SS, Kim DK, Lee SM, Yim JJ, Yang SC, Yoo CG, Chung HS, Kim YW, Han SK, Shim YS. The impact of combined pulmonary brosis and emphysema on mortality. Int J Tuberc Lung Dis. 2011;15:1111–6.
191.\Kim YS, Jin GY, Chae KJ, Han YM, Chon SB, Lee YS, Kwon KS, Choi HM. Visually strati ed CT honeycombing as a survival predictor in combined pulmonary brosis and emphysema. Br J Radiol. 2015;88:20150545.
192.\Malli F, Papakosta D, Antoniou K, Dimadi M, Polychronopoulos V, Malagari K, Oikonomou A, Bouros DE, Daniil Z. Combined pulmonary brosis and emphysema characteristics in a Greek cohort. ERJ Open Res. 2019;5:00014.
193.\Gürün Kaya A, Özyürek BA, Şahin Özdemirel T, Öz M, Erdoğan Y. Prognostic signi cance of red cell distribution width in idiopathic pulmonary brosis and combined pulmonary brosis emphysema. Med Princ Pract. 2021;30:154–9.
194.\Sugino K, Nakamura Y, Ito T, Isshiki T, Sakamoto S, Homma S. Comparison of clinical characteristics and outcomes between combined pulmonary brosis and emphysema associated with usual interstitial pneumonia pattern and non-usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2015;32:129–37.
195.\Zeba F, Yanning W, Melek J, Duan F, Atalay MK, Jankowich M, Rounds S. Prognostic signi cance of pulmonary artery to aorta ratio and other CT markers in pulmonary brosis with and without emphysema. Lung. 2021;199:677–80.
196.\Lee G, Kim KU, Lee JW, Suh YJ, Jeong YJ. Serial changes and prognostic implications of CT ndings in combined pulmonarybrosis and emphysema: comparison with brotic idiopathic interstitial pneumonias alone. Acta Radiol. 2017;58:550–7.
197.\Oh JY, Lee YS, Min KH, Hur GY, Lee SY, Kang KH, Shim JJ. Presence of lung cancer and high gender, age, and physiology score as predictors of acute exacerbation in combined pulmonary brosis and emphysema: a retrospective study. Medicine (Baltimore). 2018;97:e11683.
198.\Cottin V, Hansell DM, Antoniou KM, Nair A, Atwood M, Bradford WZ, Oster G, Kirshchgässler K, Weber F, Weycker D, Collard HR, Wells AU. The infuence of concurrent emphysema on pulmonary function decline in idiopathic pulmonary brosis (abstract). Am J Respir Crit Care Med. 2014;189:A1427.
199.\Zhao A, Gudmundsson E, Mogulkoc N, Jones MG, van Moorsel C, Corte TJ, Romei C, Savas R, Brereton CJ, van Es HW, Jo H, De Liperi A, Unat O, Pontoppidan K, van Beek F, Veltkamp M, Hopkins P, Moodley Y, Taliani A, Tavanti L, Gholipour B, Nair A, Janes S, Stewart I, Barber D, Alexander DC, Wells AU, Jacob J. Mortality in combined pulmonary brosis and emphysema patients is determined by the sum of pulmonary brosis and emphysema. ERJ Open Res. 2021;7:00316.
200.\Antoniou KM, Hansell DM, Rubens MB, Marten K, Desai SR, Siafakas NM, Nicholson AG, du Bois RM, Wells AU. Idiopathic pulmonary brosis: outcome in relation to smoking status. Am J Respir Crit Care Med. 2008;177:190–4.
201.\Cottin V. Combined pulmonary brosis and emphysema: bad and ugly all the same? Eur Respir J. 2017;50:1700846.
202.\Sergiacomi G, Bolacchi F, Cadioli M, Angeli ML, Fucci F, Crusco S, Rogliani P, Pezzuto G, Romeo F, Mariano E, Simonetti G. Combined pulmonary brosis and emphysema: 3D time- resolved MR angiographic evaluation of pulmonary arterial mean transit time and time to peak enhancement. Radiology. 2010;254:601–8.
203.\Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J. 2008;31:1357–67.
204.\Nathan SD, CottinV. Pulmonary hypertension in patients with idiopathic pulmonary brosis. Eur Respir Monogr. 2012;57:148–60.
205.\Schiess R, Senn O, Fischler M, Huber LC, Vatandaslar S, Speich R, Ulrich S. Tobacco smoke: a risk factor for pulmonary arterial hypertension? A case-control study. Chest. 2010;138:1086–92.
206.\Ferrer E, Peinado VI, Castaneda J, Prieto-Lloret J, Olea E, Gonzalez-Martin MC, Vega-Agapito MV, Diez M, Dominguez- Fandos D, Obeso A, Gonzalez C, Barbera JA. Effects of cigarette smoke and hypoxia on pulmonary circulation in the guinea pig. Eur Respir J. 2011;38:617–27.
207.\Henno P, Boitiaux JF, Douvry B, Cazes A, Levy M, Devillier P, Delclaux C, Israel-Biet D. Tobacco-associated pulmonary vascular dysfunction in smokers: role of the ET-1 pathway. Am J Physiol Lung Cell Mol Physiol. 2011;300:L831–9.
208.\Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, Olsson KM, Peacock AJ, Pepke-Zaba J, Provencher S, Weissmann N, Seeger W. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019;53:1801914.
209.\Sato S, Tanino Y, Misa K, Fukuhara N, Nikaido T, Uematsu M, Fukuhara A, Wang X, Ishida T, Munakata M. Identi cation of clinical phenotypes in idiopathic interstitial pneumonia with pulmonary emphysema. Intern Med. 2016;55:1529–35.
210.\Chae KJ, Jin GY, Han YM, Kim YS, Chon SB, Lee YS, Kwon KS, Choi HM, Lynch D. Prevalence and progression of combined pulmonary brosis and emphysema in asymptomatic smokers: a case-control study. Eur Radiol. 2015;25:2326–34.
211.\Chen Q, Liu P, Zhou H, Kong H, Xie W. An increased risk of lung cancer in combined pulmonary brosis and emphysema patients with usual interstitial pneumonia compared with patients with idiopathic pulmonary brosis alone: a systematic review and meta- analysis. Ther Adv Respir Dis. 2021;15:17534666211017050.
212.\Usui K, Tanai C, Tanaka Y, Noda H, Ishihara T. The prevalence of pulmonary brosis combined with emphysema in patients with lung cancer. Respirology. 2011;16:326–31.
33 The Syndrome of Combined Pulmonary Fibrosis and Emphysema |
587 |
|
|
213.\Sato S, Koike T, Hashimoto T, Ishikawa H, Okada A, Watanabe T, Tsuchida M. Surgical outcomes of lung cancer patients with combined pulmonary brosis and emphysema and those with idiopathic pulmonary brosis without emphysema. Ann Thorac Cardiovasc Surg. 2016;22:216–23.
214.\Miyamoto A, Kurosaki A, Moriguchi S, Takahashi Y, Ogawa K, Murase K, Hanada S, Uruga H, Takaya H, Morokawa N, Fujii T, Hoshino J, Kishi K. Reduced area of the normal lung on high-resolution computed tomography predicts poor survival in patients with lung cancer and combined pulmonary brosis and emphysema. Respir Investig. 2019;57:140–9.
215.\Mimae T, Suzuki K, Tsuboi M, Nagai K, Ikeda N, Mitsudomi T, Saji H, Okumura S, Okumura M,Yoshimura K, Okada M. Surgical outcomes of lung cancer in patients with combined pulmonary brosis and emphysema. Ann Surg Oncol. 2015;22(Suppl 3):S1371–9.
216.\Hata A, Sekine Y, Kota O, Koh E, Yoshino I. Impact of combined pulmonary brosis and emphysema on surgical complications and long-term survival in patients undergoing surgery for non-small- cell lung cancer. Int J Chron Obstruct Pulm Dis. 2016;11:1261–8.
217.\Hashimoto N, Iwano S, Kawaguchi K, Fukui T, Fukumoto K, Nakamura S, Mori S, Sakamoto K, Wakai K, Yokoi K, Hasegawa Y. Impact of thin-section computed tomography-determined combined pulmonary brosis and emphysema on outcomes among patients with resected lung cancer. Ann Thorac Surg. 2016;102:440–7.
218.\Gao L, Xie S, Liu H, Liu P, Xiong Y, Da J, Que C, Dai H, Wang C. Lung cancer in patients with combined pulmonary brosis and emphysema revisited with the 2015 World Health Organization classi cation of lung tumors. Clin Respir J. 2018;12:652–8.
219.\Koo HJ, Do KH, Lee JB, Alblushi S, Lee SM. Lung cancer in combined pulmonary brosis and emphysema: a systematic review and meta-analysis. PLoS One. 2016;11:e0161437.
220.\Maeda R, Funasaki A, Motono N, Sekimura A, Usuda K, Uramoto H. Combined pulmonary brosis and emphysema predicts recurrence following surgery in patients with stage I non-small cell lung cancer. Med Oncol. 2018;35:31.
221.\Vancheri C. Common pathways in idiopathic pulmonary brosis and cancer. Eur Respir Rev. 2013;22:265–72.
222.\Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonarybrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010;35:496–504.
223.\Saito H, Minamiya Y, Nanjo H, Ito M, Ono T, Motoyama S, Hashimoto M, Ogawa J. Pathological nding of subclinical interstitial pneumonia as a predictor of postoperative acute respiratory distress syndrome after pulmonary resection. Eur J Cardiothorac Surg. 2011;39:190–4.
224.\Minegishi Y, Takenaka K, Mizutani H, Sudoh J, Noro R, Okano T, Azuma A, Yoshimura A, Ando M, Tsuboi E, Kudoh S, Gemma A. Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med. 2009;48:665–72.
225.\Ikuyama Y, Ushiki A, Kosaka M, Akahane J, Mukai Y, Araki T, Kitaguchi Y, Tateishi K, Urushihata K, Yasuo M, Yamamoto H, Hanaoka M. Prognosis of patients with acute exacerbation of combined pulmonary brosis and emphysema: a retrospective single-centre study. BMC Polm. 2020;20:144.
226.\Antoniou KM, Wells AU. Acute exacerbations of idiopathic pulmonary brosis. Respiration. 2013;86:265–74.
227.\Judge EP, Fabre A, Adamali HI, Egan JJ. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary brosis. Eur Respir J. 2012;40:93–100.
228.\Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, Taglieri A, Mezzasalma F, Rottoli P, Saltini C, Rogliani P. Predicting survival in newly diagnosed idiopathic pulmonary brosis: a 3-year prospective study. Eur Respir J. 2012;40:101–9.
229.\Zantah M, DotanY, Dass C, Zhao H, Marchetti N, Criner GJ. Acute exacerbations of COPD versus IPF in patients with combined pulmonary brosis and emphysema. Respir Res. 2020;21:164.
230.\Hyldgaard C, Hilberg O, Bendstrup E. How does comorbidity infuence survival in idiopathic pulmonary brosis? Respir Med. 2014;108:647–53.
231.\Jacobs SS, Krishnan JA, Lederer DJ, Ghazipura M, Hossain T, Tan AM, Carlin B, Drummond MB, Ekström M, Garvey C, Graney BA, Jackson B, Kallstrom T, Knight SL, Lindell K, Prieto-Centurion V, Renzoni EA, Ryerson CJ, Schneidman A, Swigris J, Upson D, Holland AE. Home oxygen therapy for adults with chronic lung disease. an of cial American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202:e121–41.
232.\Tomioka H, Mamesaya N, Yamashita S, Kida Y, Kaneko M, Sakai H. Combined pulmonary brosis and emphysema: effect of pulmonary rehabilitation in comparison with chronic obstructive pulmonary disease. BMJ Open Resp Res. 2016;3:e000099.
233.\Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, Nunes H, Wémeau-Stervinou L, Bergot E, Blanchard E, Borie R, Bourdin A, Chenivesse C, Clément A, Gomez E, Gondouin A, Hirschi S, Lebargy F, Marquette CH, Montani D, Prévot G, Quetant S, Reynaud-Gaubert M, Salaun M, Sanchez O, Trumbic B, Berkani K, Brillet PY, Campana M, Chalabreysse L, Chatté G, Debieuvre D, Ferretti G, Fourrier JM, Just N, Kambouchner M, Legrand B, Le Guillou F, Lhuillier JP, Mehdaoui A, Naccache JM, Paganon C, Rémy-Jardin M, Si-Mohamed S, Terrioux P. [French practical guidelines for the diagnosis and management of IPF - 2021 update, short version]. Rev Mal Respir. 2022;39:275.
234.\Wijsenbeek M, Cottin V. Spectrum of brotic lung diseases. N Engl J Med. 2020;383:958–68.
235.\Takahashi T, Terada Y, Pasque MK, Liu J, Byers DE, Witt CA, Nava RG, Puri V, Kozower BD, Meyers BF, Kreisel D, Patterson GA, Hachem RR. Clinical features and outcomes of combined pulmonary brosis and emphysema after lung transplantation. Chest. 2021;160:1753.
236.\Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM. Pirfenidone in patients with idiopathic pulmonary brosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–9.
237.\Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR. Ef cacy and safety of nintedanib in idiopathic pulmonary brosis. N Engl J Med. 2014;370:2071–82.
238.\King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary brosis. N Engl J Med. 2014;370:2083–92.
239.\Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme- Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK, Investigators IT. Nintedanib in progressive brosing interstitial lung diseases. N Engl J Med. 2019;381:1718–27.
240.\Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, Bonnet R, Grohe C, Held M, Wilkens H, Hammerl P, Koschel D, Blaas S, Wirtz H, Ficker JH, Neumeister W, Schönfeld N, Claussen M, Kneidinger N, Frankenberger M, Hummler S, Kahn N, Tello S, Freise J, Welte T, Neuser P, Günther A. Pirfenidone in patients with progressive brotic interstitial lung diseases other than idiopathic pulmonary brosis (RELIEF): a double-blind, ran-
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
588 |
V. Cottin |
|
|
domised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9:476–86.
241.\Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina- Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V. Pirfenidone in patients with unclassi able progressive brosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8:147–57.
242.\Cottin V, Azuma A, Raghu G, Stansen W, Stowasser S, Schlenker- Herceg R, Kolb M. Therapeutic effects of nintedanib are not infuenced by emphysema in the INPULSIS trials. Eur Respir J. 2019;53:1801655.
243.\Huie TJ, Solomon JJ. Emphysema and pulmonary brosis: coincidence or conspiracy? Respirology. 2013;18:1163–4.
244.\Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G. Anti-acid treatment and disease progression in idiopathic pulmonary brosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013;1:369–76.
245.\Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46:903–75.
246.\Shioleno AM, Ruopp NF. Group 3 pulmonary hypertension: a review of diagnostics and clinical trials. Clin Chest Med. 2021;42:59–70.
247.\Hoeper MM, Behr J, Held M, Grunig E, Vizza CD, Vonk- Noordegraaf A, Lange TJ, Claussen M, Grohe C, Klose H, Olsson KM, Zelniker T, Neurohr C, Distler O, Wirtz H, Opitz C, Huscher D, Pittrow D, Gibbs JS. Pulmonary hypertension in patients with chronic brosing idiopathic interstitial pneumonias. PLoS One. 2015;10:e0141911.
248.\Zimmermann GS, von Wulffen W, Huppmann P, Meis T, Ihle F, Geiseler J, Leuchte HH, Tufman A, Behr J, Neurohr C. Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors. Respirology. 2014;19:700–6.
249.\Cottin V. Clinical case: combined pulmonary brosis and emphysema with pulmonary hypertension - clinical management. BMC Res Notes. 2013;6(Suppl 1):S2.
250.\Roccia F, Campolo B, Gallelli L, Spaccarotella C, Mongiardo A, Falcone D, Savino R, Pelaia G, Indol C, Maselli R. Effects of
ambrisentan in a patient affected by combined pulmonary brosis and emphysema and by severe pulmonary hypertension: clinical, functional, and biomolecular ndings. Clin Drug Investig. 2013;33:451–7.
251.\Mercurio V, Carlomagno G, Fazio S. Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: case report and review of the literature. Heart Lung. 2012;41:512–7.
252.\Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363:620–8.
253.\Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ. Nintedanib plus sildena l in patients with idiopathic pulmonary brosis. N Engl J Med. 2018;379:1722–31.
254.\Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR, Costabel U, Richeldi L, de Andrade J, Khalil N, Morrison LD, Lederer DJ, Shao L, Li X, Pedersen PS, Montgomery AB, Chien JW, O’Riordan TG. Treatment of idiopathic pulmonary brosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013;158:641–9.
255.\Nathan SD, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez FJ, Corte TJ, Keogh AM, Leuchte H, Mogulkoc N, Ulrich S, Wuyts WA, Yao Z, Boateng F, Wells AU. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE- IIP): a randomised, placebo-controlled phase 2b study. Lancet Respir Med. 2019;7:780–90.
256.\Nathan SD, Cottin V, Behr J, Hoeper MM, Martinez FJ, Corte TJ, Keogh AM, Leuchte H, Mogulkoc N, Ulrich S, Wuyts WA, Yao Z, Ley-Zaporozhan J, Müller-Lisse UG, Scholle FD, Brüggenwerth G, Busse D, Nikkho S, Wells AU. Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: a post hoc subgroup analysis of the RISE-IIP study. J Heart Lung Transplant. 2021;40:494–503.
257.\Waxman A, Restrepo-Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A, Allen R, Feldman J, Argula R, Smith P, Rollins K, Deng C, Peterson L, Bell H, Tapson V, Nathan SD. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med. 2021;384:325–34.
258.\Nathan SD, Waxman A, Rajagopal S, Case A, Johri S, DuBrock H, De La Zerda DJ, Sahay S, King C, Melendres-Groves L, Smith P, Shen E, Edwards LD, Nelsen A, Tapson VF. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. Lancet Respir Med. 2021;9:1266–74.